Production of Methioninase from Serratia Marcescens Isolated from Soil and its Anti-Cancer Activity against Dalton’s Lymphoma Ascitic (DLA) and Ehrlich Ascitic Carcinoma (EAC) in Swiss Albino Mice
Purpose: To evaluate the anticancer activity of an enzyme, methioninase, obtained from a soil isolate, Serratia marcesens, against Dalton’s lymphoma ascitic (DLA) and Ehrlich ascitic carcinoma (EAC) in Swiss albino mice.
Methods: Cancer was induced using DLA and EAC cells in Swiss albino mice by intraperitoneal injection. The mice were then treated with 10 and 20 mg/kg body weight of methioninase; 5-fluorouracil (5-FU) was used as standard.
Results: The results showed good improvement in haematological parameters, improvement serum enzymes and lipid profile, as well as increase in life span by up to 77 %, increase in body weight (p < 0.01), decrease in cancer cell count from (2.70 ± 0.40) × 106 to (1.86 ± 0.30) × 106 cells/ml compared to (2.70 ± 0.40) × 106 to (1.42 ± 0.25) x 106 cells/ml for the group treated with 5-FU. Solid tumor volume decreased from 5.82 ± 0.15 to 4.10 ± 0.11 ml as as against a decrease from 5.82 ± 0.40 to 3.56 ± 0.28 for the group treated with 5-FU.
Conclusion: The isolated enzyme, methioninase, has a good anti-cancer activity and needs to be further be investigated for this activity.
Keywords: Methioninase, Anticancer, Serum depletion, Tumor, Dalton’s lymphoma ascetic, Ehrlich ascitic carcinoma
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.